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Abst ract
Background and purpose: The influence of sex hormones on
immune system activity in multiple sclerosis (MS) has been
suggested by clinical evidence. The aim of the study was to
ana lyse the pattern of sex hormones in MS women and to cor-
relate the hormone pattern abnormalities to the disease course
as well as to the magnetic resonance imaging (MRI) results.
Material and methods:We studied the serum level of the pro -
gesterone, β-oestradiol and prolactin in 46 women with clin-
ical definite MS aged from 19 to 65; mean disease duration
was 11.80 ± 9.86 years. The evaluation of the intensity of hor-
monal changes was done using a scoring system (0-3). On the
brain MRI, the presence of brain atrophy, of hypothalamic 
demyelination as well as demyelination intensity (or degree)
were analysed. The evaluation of the degree of demyelination
and brain atrophy was done using a scoring system (0-4).
Results: The main hormonal abnormalities consisted of decreased
progesterone level, increased oestradiol level or both. The sex
hormone pattern was abnormal in 56% of patients. Hypotha -
lamic lesions were found on MRI in 53% of cases. The abnormal
hormonal pattern correlated with intensity of MR changes 
(p < 0.05, Fisher’s exact test), but neither with presence of 
hypothalamic changes nor with disease parameters (Expand-
ed Disability Status Scale, relapse rate, disease duration).
Sex hormone patterns in women with multiple sclerosis as related to 
disease activity – a pilot study
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St reszc zenie
Wstêp i cel pracy: Dane z piœmiennictwa sugeruj¹ czêste wy-
stêpowanie zaburzeñ hormonalnych u kobiet chorych na
stwardnienie rozsiane (SR). Celem pracy by³a analiza profi-
lu hormonalnego w zakresie hormonów p³ciowych u kobiet
z SR w powi¹zaniu z przebiegiem klinicznym i obrazem re-
zonansu magnetycznego (RM) mózgowia.
Materia³ i metody: Badano stê¿enie progesteronu, β-estradiolu
i prolaktyny w surowicy u 46 pacjentek z klinicznie pewnym
SR, w wieku od 19 lat do 65 lat, o œrednim czasie trwania cho-
roby 11,80 ± 9,86 roku, niestosuj¹cych ¿adnej terapii hor-
monalnej. Stopieñ zmian w profilu hormonalnym oceniano
pó³iloœciowo wg przyjêtego arbitralnie przez autorów systemu
punktacji (0–3).W analizie RM brano pod uwagê obecnoœæ
ognisk demielinizacji w obrêbie struktur podwzgórza, nasi-
lenie demielinizacji w obrêbie mózgowia oraz wspó³istnienie
zaniku mózgu. Stopieñ zmian w RM oceniano tak¿e pó³ilo-
œciowo wg przyjêtego arbitralnie przez autorów systemu
punktacji (0–4).
Wyniki: Nieprawid³owe stê¿enia hormonów stwierdzono
u 26 pacjentek (56%). Nieprawid³owoœci polega³y na zmniej-
szonym stê¿eniu progesteronu, zwiêkszonym stê¿eniu 
17-β-estradiolu b¹dŸ na ³¹cznym wystêpowaniu obu tych za-
burzeñ. W badaniu RM w 53% przypadków stwierdzono
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Introduction
Multiple sclerosis (MS) is an autoimmune disease,
characterized by a chronic inflammatory demyelinating
process in the central nervous system (CNS). Females
have an increased risk of developing autoimmune dis-
eases such as rheumatoid arthritis (RA) and MS com-
pared to males. Relapsing-remitting MS (RRMS) af-
fects females two to three times more often than males
[1-3]. Although the mechanism for gender dispropor-
tion related to susceptibility and disease progression in
MS is unclear, increasing evidence suggests that sex hor-
mones play an important role [4-8]. For example, the cli -
ni cal signs of MS usually appear in young adults, after
sexual maturity. Other periods of change in serum sex
hormone concentrations, such as during menstruation and
the menopause, may also negatively affect the course of
MS [9-11]. Little is known about the influence of oral
contraceptives on the modulation of the disease activity
in MS [12]. More evidence for a role of sex hormones
in MS is observed during pregnancy [13-15]. Indeed,
increased level of sex hormones produced during preg-
nancy have been reported to reduce the severity of MS,
whereas in a period of time marked by reduced sex hor-
mones, such as the postpartum period, clinical symptoms
of MS often increase. Pregnancy is associated with en-
 hanced humoral and decreased cellular immune acti vity
[16,17].
The goal of this article is to analyse the pattern of
sex hormones in MS women and to correlate the hor-
monal pattern abnormalities with the clinical course of
the disease and to the magnetic resonance imaging
(MRI) results.
Material and methods
Subjects
The study group included 46 women with clinically
definite MS diagnosed according to the criteria proposed
by McDonald et al. [18]. The control group for hormonal
study consisted of 50 healthy women matched for age and
hormonal status (premenopausal and postmenopausal). 
Sex hormone levels obtained in the control group of
healthy women were usually accepted as normal; if in
a given case results markedly exceeded the limits obtained
in the control group (“outsiders”) that person was not in-
cluded in the control group. The hormone mean values
and ranges found in controls are presented in Table 1.
The patients were recruited from MS Outpatient
Clinic and MS Unit, Department of Neurology, The Me -
dical University of Warsaw. Their characteristics are pro-
vided in Table 2. There were 27 patients with RRMS,
12 with secondary progressive course (SPMS) and 7 with
Conclusions: It is important to check the hormonal pattern in
MS women because according to our results it may be relat-
ed to the disease activity and probably affects the type of the -
rapeutic intervention. This pilot study will be extended in a larg-
er population.
Key words: sex hormones, MRI, multiple sclerosis.
obecnoœæ zmian demielinizacyjno-zapalnych w obrêbie pod-
wzgórza. Stopieñ zaburzeñ hormonalnych oceniany pó³iloœcio -
wo korelowa³ ze stopniem zmian w RM mózgowia (p< 0,05;
test dok³adny Fishera), nie by³ natomiast zwi¹zany z obecnoœci¹
zmian w obrêbie podwzgórza czy parametrami klinicznymi
(punktacja wExpanded Disability Status Scale, czêstoœæ rzutów,
czas trwania choroby).
Wnioski: Stan hormonalny kobiet chorych na SR powinien
byæ brany pod uwagê w analizie klinicznej choroby i przy de-
cyzjach terapeutycznych, gdy¿ wydaje siê mieæ zwi¹zek z ak-
tywnoœci¹ SR. Badania te, w celu potwierdzenia uzyskanych
wyników, nale¿y kontynuowaæ na szerszym materiale.
S³owa kluczowe: hormony p³ciowe, rezonans magnetyczny,
stwardnienie rozsiane.
Menstrual cycle 17-β-oestradiol Progesterone
phases
Mean and range Mean and range
(pg/mL) (nmol/L)
Follicular phase 102.0 2.10
(35.0-169.0) (1.21-2.99)
Ovulation 238.0 Not
(49.0-427.0) detectable
Luteal phase 122.0 55.31
(53.0-191.0) (24.71-85.90)
Postmenopausal 64.0 1.08
period (18.0-110.0) (0.60-1.56)
Table 1. Hormone value ranges in controls
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relapsing-progressing MS (RPMS). Hormonal and
MRI studies were performed during thet follicular phase
in 14 patients, during the luteal phase in 12 pa tients, dur-
ing ovulation in 1 woman. In 19 women hormonal eval-
uation has confirmed postmenopausal state. Neither pa-
tients nor controls have received any hormonal therapy,
including hormonal contraception. There was no rele-
vant gynaecological history in the control group. The pa-
tients’ gynaecological symptoms and signs were also in-
significant except for mild menstrual disturbances
occurring in 50% of patients, consisting of irregular men-
struation. All subjects gave their informed consent prior
to their inclusion in the study. Brain MR as well as hor-
monal panel are a part of the standard procedures per-
formed in the MS Unit.
Magnetic resonance imaging
On MRI examination, conventional spin echo sequen -
ces were used to obtain proton density and T2-weight -
ed images of the brain. The T1-weighted images were also
analysed. The MR images were evaluated according to
an arbitrarily proposed semi-qualitative scoring system
used in our MS Unit. Such evaluation was performed
by an experienced neuroradiologist. It was impossible to
perform qualitative MRI analysis for technical reasons.
The evaluation of the degree of demyelination and brain
atrophy was done using a scoring system (Table 3). In
addition, on 36 scans it was possible to analyse the pre -
sence and then to assess the number of T2-weighted hy-
po thalamic lesions.
Hormonal studies
At the day of MR study (± 7 days), serum levels of
17-β-oestradiol (pg/mL), progesterone (ng/L) and
prolactin (ng/mL) were determined. Blood samples were
stored at –20°C until analysis. Single measurement of 
the level of sex hormones is insufficient from an endocrine
and gynaecological point of view to make a precise dia -
gnosis of possible disturbances and in this study it ser -
ves only as a basis for preliminary conclusions and for
comparison with the control group. Hormonal evalua-
tions were blinded and performed in a single radioim-
munoassay for each hormone. The evaluation of the in-
tensity of hormonal changes was done using a scoring
system (Table 4). The hormone levels were analysed sep-
arately for each hormone and for each hormonal phase.
For example, the pro gesterone level was considered ab-
normal in the follicular phase if it was < 1.21 nmol/L
or > 2.99 nmol/L.
Statistical analysis
Values are presented as mean ± SD as well as means
and ranges. The Spearman correlation coefficients test
was used to study the correlations between the follow-
ing variables: Expanded Disability Status Scale (EDSS),
age, disease duration, relapse index and MRI as well as
hormonal scores. Wilcoxon rank-sum test was used to
analyse the differences between patients and controls.
Fisher exact test was used to study the associations be-
tween different parameters, i.e. hormonal and MR scores
in different subgroups. Statistical significance was de-
fined as p< 0.05.
MRI abnormalities 
(scores)
0 Normal brain MRI
1 Moderate multifocal demyelination
2 Marked multifocal demyelination
3 Marked diffuse demyelination
4 Marked diffuse and multifocal 
demyelination and brain atrophy
Table 3. Magnetic resonance imaging (MRI) analysis: scoring system
Characteristics Multiple sclerosis patients
Number of patients 46
Age [years];  39.28 ± 11.67 (19-65)
mean ± SD (range)
Multiple sclerosis duration 11.80 ± 9.86 (0.5-39.0)
[years]; mean ± SD (range)
Relapse Index;  2.24 ± 2.60 (1-12)
mean ± SD (range)
EDSS; mean ± SD (range) 3.51 ± 1.71 (1-7)
Table 2. Demographic characteristics of multiple sclerosis patients
SD – standard deviation, EDSS – Expanded Disability Status Scale
Hormone Progesterone 7-β-oestradiol 
abnormalities serum level serum level
(scores)
0 Normal Normal
1 Decreased Normal
2 Normal Increased
3 Decreased Increased
Table 4. Hormone pattern analysis: scoring system
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Results
Hormonal changes
The mean hormone levels in the MS patient group
were as follows: 137.7 ± 144.26 pg/mL for oestradiol,
6.41 ± 11.59 nmol/L for progesterone and 93.29 ±
344.21 ng/mL for prolactin (prolactin level ranges in con-
trols were from 1.2 to 29.93 ng/ml). These results in dif-
ferent cycle phases (hormones’ mean values and ranges)
compared with the control group are presented in 
Fig. 1. The oestradiol level was abnormal in 12 patients
(26.1%), the progesterone level in 21 (45.6%) and the
prolactin in 5 cases (10.9%). Because of the small num-
ber of patients in each subgroup, statistical comparison
of the sex hormone level differences between MS patients
and the control groups in particular phases of the men-
strual cycle was not possible. The distribution of the de-
gree of hormonal changes (in scores) is presented in 
Fig. 2. In general, hormonal abnormalities were found
in 26 MS women (56.5%) and were usually of mild in-
tensity (score 1). 
Magnetic resonance imaging changes
Hypothalamic lesions were found on MRI in 17 of
36 analysed cases (53%). The distribution of the degree
of MR changes (in scores) is presented in Fig. 3. This
distribution was almost equal for scores 1, 2 and 4.
Fig. 1. Hormone levels in multiple sclerosis (MS) patients and controls (means and ranges): A) follicular phase and B) luteal phase
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Hormonal versus MR changes
The significant associations were found between hor-
monal and MR score distribution if studied by Fisher’s
exact test (p< 0.05).
Neither the hormonal nor MR scores were related to
the clinical parameters (i.e. the age of the patients, the MS
duration, the EDDS value as well as the relapse index).
There was no correlation between the presence and
the number of hypothalamic lesions on MR and the hor-
monal change scores. Especially the presence and the
number of hypothalamic lesions were not closely relat-
ed to the prolactin level if studied by Wilcoxon two sam-
ples and by Kruskal-Wallis test.
Discussion
It seems that sex hormones play an important role in
susceptibility to MS and in disease progression. In our
material the oestradiol level was abnormal (increased) 
in about one-fourth of patients, whereas both oestrogen
(high) and progesterone (low) levels were abnormal in
about half of patients.
Oestrogen has a dichotomous effect on the immune
system [19]. For example, T cell development in the thy-
mus is suppressed, whereas antibody production is sti -
mulated by oestrogen [20,21]. Furthermore, oestrogen
decreases T-cell mediated delayed-type hypersensitivity
[21,22], granulocyte-mediated cytotoxicity and natur-
al killer-mediated cytotoxicity [22,23]. Oestrogens are
considered to differentially affect immune responses dur-
ing pregnancy, during the menstrual cycle, and in post-
menopausal women [6,19]. During pregnancy, oestro-
gens play an important role in regulating physiological
events essential to the maintenance of the fetus and the
protection of the mother, but may also influence the cli -
nical course of MS [24-26]. Indeed, in MS it is well
known that late pregnancy affords temporal remission of
MS attacks [27]. The clinical remission is also associat-
ed with a decrease of the disease activity on the MRI 
[28-30]. Women who first developed symptoms of MS
during pregnancy experience less subsequent disability
than women who developed the disease at any other time
[31]. Besides the possible immune modulation by oe-
stro gen during pregnancy, it can be anticipated that oral
contraception similarly affects the immune system. 
Although no data in MS have been reported about the
long-term effects of oral contraception, the effects of oral
contraception in rheumatoid arthritis (RA) have been 
debated. No definite conclusion could be drawn, since
a beneficial effect has been documented in some earlier
studies, while in others oral contraception has no effect
[32-35]. This may reflect the reduced amount of oestro -
gen in more recent oral contraceptives and the use of syn-
thetically modified oestrogen [36].
The exact role of progesterone in MS remains un-
clear [37,38]. It might modify the cytokine production
in MS [39]. Pozzilli et al. [40] found that increased ra-
tio of progesterone/17-β-oestradiol during the luteal phase
was associated with both a high number and volume of
enhancing lesions on MRI. In our study we have con-
firmed the relationship between this ratio and the degree
of MR changes. During pregnancy, the placenta produces
a high level of progesterone responsible for the immu -
nosuppressive effect. Contrarily, Correale et al.[14] found
in MS that progestrone, in concentrations similar to that
found in the peripheral circulation during the normal
menstruation, during pregnancy, as well as in pharma-
cological doses, enhanced  secretion of IL-4 by periphe-
ral CD4+T cells. Since IL-4 plays an important role in
Score 0 Score 1 Score 2 Score 3 
25
20
15
10
5
0
HHoo
rrmm
oonn
ee  aa
bbnn
oorrmm
aallii
ttiiee
ss  [[
nn]]
Fig. 2. Hormonal abnormalities distribution (in scores) in multiple sclerosis
patients
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Fig. 3. MRI abnormalities distribution (in scores) in multiple sclerosis patients
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the development of Th2 cells, progesterone seems to be
a good candidate for their promotion.
In our study we analysed the MR abnormalities in
relation to hormonal changes. The clinical remission in
MS is usually associated with a decrease of the disease
activity on the MRI [28]. Some studies revealed gen-
der-associated differences in clinical evolution of MS as
well as in the evolution of MRI findings. Female patients
are more likely to develop more inflammatory but less 
destructive lesion pathology. There was a trend toward
higher lesion volume in T1-weighted images and high-
er ratio T1/T2-weighted lesions when comparing male
to female with RRMS. Women showed a smaller num-
ber of Gd-enhancing lesions [41]. These results indi-
cated a gender effect on MRI findings in MS using con-
ventional MRI techniques [42].
We tried to correlate the MRI findings and clinical
MS parameters. Our results were unrelevant. Particu-
larly there was no relationship between hormonal ab-
normalities and presence and/or number of hypothala-
mic lesions. 
Conclusions
The molecular basis for explaining the hormonal pat-
tern related differences in MRI findings in women with
MS and the underlying pathological process translating
the disease activity in general, as well as in our study, in
MRI-related measures remains unclear, although a di-
vergent imbalance between demyelination, inflammation
and neurodegeneration related to hormonal patterns is
proposed. To confirm the obtained results our pilot study
should be extended to a larger patient population.
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